Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Receivables (2017 - 2025)

Alterity Therapeutics has reported Receivables over the past 3 years, most recently at $3.4 million for Q2 2019.

  • For Q2 2019, Receivables rose 41.75% year-over-year to $3.4 million; the TTM value through Jun 2019 reached $3.4 million, up 41.75%, while the annual FY2019 figure was $3.4 million, 41.75% up from the prior year.
  • Receivables for Q2 2019 was $3.4 million at Alterity Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Receivables peaked at $3.4 million in Q2 2019 and troughed at $2.3 million in Q2 2017.
  • A 3-year average of $2.7 million and a median of $2.4 million in 2018 define the central range for Receivables.
  • Biggest five-year swings in Receivables: rose 4.65% in 2018 and later surged 41.75% in 2019.
  • Year by year, Receivables stood at $2.3 million in 2017, then rose by 4.65% to $2.4 million in 2018, then surged by 41.75% to $3.4 million in 2019.
  • Business Quant data shows Receivables for ATHE at $3.4 million in Q2 2019, $2.4 million in Q2 2018, and $2.3 million in Q2 2017.